Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

dc.contributor.authorSinnollareddy, Mahipal
dc.contributor.authorSousa, Eduardo
dc.contributor.authorSoy Muner, Dolors
dc.contributor.authorSpring, Anna
dc.contributor.authorStarr, Therese
dc.contributor.authorStephens, Dianne
dc.contributor.authorTaccone, Fabio Silvio
dc.contributor.authorThomas, Jane
dc.contributor.authorTurnidge, John
dc.contributor.authorValkonen, Miia
dc.contributor.authorDe Waele, Jan J.
dc.contributor.authorVarghese, Julie M.
dc.contributor.authorDeans, Renae
dc.contributor.authorWallis, Steven C.
dc.contributor.authorDonnellan, Sine
dc.contributor.authorWalker, Robert J.
dc.contributor.authorEastwood, Glenn M.
dc.contributor.authorWilliams, Tricia
dc.contributor.authorFrey, Otto R.
dc.contributor.authorWilson, Luke C.
dc.contributor.authorGoutelle, Sylvain
dc.contributor.authorWittebole, Xavier
dc.contributor.authorGresham, Rebecca
dc.contributor.authorAin Jamal, Janattul
dc.contributor.authorJoynt, Gavin M.
dc.contributor.authorKanji, Salmaan
dc.contributor.authorRoberts, Jason A.
dc.contributor.authorUlldemolins, Marta
dc.contributor.authorLiu, Xin
dc.contributor.authorBaptista, João P.
dc.contributor.authorBilgrami, Irma
dc.contributor.authorBoidin, Clement
dc.contributor.authorBrinkmann, Alexander
dc.contributor.authorCastro, Pedro
dc.contributor.authorChoi, Gordon
dc.contributor.authorCole, Louise
dc.contributor.authorWright, Daniel F.B.
dc.contributor.authorZikou, Xanthi T.
dc.contributor.authorBellomo, Rinaldo
dc.contributor.authorLipman, Jeffrey
dc.contributor.authorKluge, Stefan
dc.contributor.authorKönig, Christina
dc.contributor.authorKoulouras, Vasilios P.
dc.contributor.authorLassig-Smith, Melissa
dc.contributor.authorLaterre, Pierre-Francois
dc.contributor.authorLee, Anna
dc.contributor.authorLefrant, Jean-Yves
dc.contributor.authorLei, Katie
dc.contributor.authorLeung, Patricia
dc.contributor.authorLlauradó Serra, Mireia
dc.contributor.authorMartín Loeches, Ignacio
dc.contributor.authorMat Nor, Mohd Basri
dc.contributor.authorMudaliar, Yugan
dc.contributor.authorOstermann, Marlies
dc.contributor.authorPaul, Sanjoy K.
dc.contributor.authorPeake, Sandra L.
dc.contributor.authorRello, Jordi
dc.contributor.authorRoberts, Darren M.
dc.contributor.authorRoberts, Michael S.
dc.contributor.authorRichards, Brent
dc.contributor.authorRodríguez, Alejandro
dc.contributor.authorRoehr, Anka C.
dc.contributor.authorRoger, Claire
dc.contributor.authorSeoane, Leonardo
dc.date.accessioned2025-12-03T16:43:52Z
dc.date.available2025-12-03T16:43:52Z
dc.date.issued2025-08-13
dc.date.updated2025-12-03T16:43:52Z
dc.description.abstractPurpose: Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics. Methods: Prospective, multinational pharmacokinetic study including patients requiring various forms of RRT. Independent population PK models were developed, externally validated and applied to perform Monte Carlo dosing simulations using Monolix and Simulx. We calculated the probability that these dosing regimens achieved standard and high therapeutic unbound antibiotic concentrations over 100% of the dosing interval for the treatment of Enterobacterales and Pseudomonas aeruginosa. Results: We enrolled 300 patients from 22 intensive care units across 12 countries receiving continuous veno-venous haemodialysis (13.0%), haemofiltration (23.3%), haemodiafiltration (48.4%) or sustained low-efficiency dialysis (15.3%). Models were developed using data from 234 patients (8322 samples) and validated with 66 additional patients (560 samples). Predictive performance was high, with mean prediction errors of - 5.2% for meropenem and - 16.9% for piperacillin. Dosing simulations showed that meropenem and piperacillin/tazobactam dosing requirements were dependent on urine output and RRT intensity and duration (p < 0.05). In all scenarios, extended/continuous infusions led to a better achievement of effective concentrations with lower daily doses compared to short infusion. Dosing nomograms were developed to inform dosing for different RRT settings, urine outputs, and target concentrations. Conclusion: RRT intensity and duration and urine output determine meropenem and piperacillin/tazobactam dosing requirements in critically ill patients receiving RRT. Extended/continuous infusions facilitate the attainment of effective concentrations.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec762181
dc.identifier.issn0342-4642
dc.identifier.pmid40801954
dc.identifier.urihttps://hdl.handle.net/2445/224652
dc.language.isoeng
dc.publisherSpringer Verlag
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s00134-025-08067-w
dc.relation.ispartofIntensive Care Medicine, 2025, vol. 51, num.9, p. 1628-1640
dc.relation.urihttps://doi.org/10.1007/s00134-025-08067-w
dc.rightscc by-nc (c) Sinnollareddy, Mahipal et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subject.classificationUnitats de cures intensives
dc.subject.classificationMalalts en estat crític
dc.subject.classificationMedicaments antibacterians
dc.subject.otherIntensive care units
dc.subject.otherCritically ill
dc.subject.otherAntibacterial agents
dc.titleMeropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
905985.pdf
Mida:
1.1 MB
Format:
Adobe Portable Document Format